137973-76-3

Basic information

• Product Name: N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide
• Synonyms: N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide;7-chloro-1-[2-methyl-4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine;N-(4-(7-Chloro-5-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)-3-methylphenyl)-2-methylbe;5-Dehydro Tolvaptan;N-(4-(7-Chloro-5-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)-3-Methylphenyl)-2-MethylbenzaMide;Dehydrotolvaptan;N-[4-[7-Chloro-2,3,4,5-Tetrahydro-5-oxo-1H-1-Benzazepine-1-yl)carbonyl]-3-MethylPhenyl]-2-MethylBenzamide;N-[4-(7-chloro-5-oxo-3,4-dihydro-2H-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
• CAS NO: 137973-76-3
• Molecular Formula: C₂₆H₂₃ClN₂O₃
• Molecular Weight: 446.93
• EINECS: 1312995-182-4
• Product Categories: Tolvaptan intermediate
• Mol File: 137973-76-3.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 593.224 °C at 760 mmHg
• Flash Point: 312.571 °C
• Appearance: /
• Density: 1.307
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.97±0.70(Predicted)
• CAS DataBase Reference: N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide(137973-76-3)
• EPA Substance Registry System: N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide(137973-76-3)

Safety Data

• Hazardous Substances Data: 137973-76-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 137973-76-3 differently. You can refer to the following data:
1. 5-Dehydro Tolvaptan is an impurity of Tolvaptan (T536650), a selective, competitive arginine vasopressin V2 receptor antagonist ngestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).
2. 5-Dehydro Tolvaptan is an impurity of Tolvaptan (T536650), a selective, competitive arginine vasopressin V2 receptor antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH g

Upstream product

• 933-88-0 ortho-toluoyl chloride 
• 137977-97-0 1-(4-amino-2-methylbenzoyl)-7-chloro-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 106-47-8 4-chloro-aniline 
• 21900-45-8 4-bromo-2-methylbenzoyl chloride 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 118-90-1 ortho-methylbenzoic acid 
• 527-85-5 o-Methylbenzamid 
• 317374-08-6 2-methyl-4-(2-methylbenzoylamino)benzoic acid 
• 160129-45-3 7-chloro-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one 
• 331947-69-4 2-methyl-4-(2-methylbenzoylamino)benzoic acid chloride 
• 7149-70-4 2-bromo-5-nitrotoluene 
• 67-56-1 methanol 
• 150683-30-0 tolvaptan 
• 247237-43-0 methyl 5-chloro-2-[N-(3-ethoxycarbonyl)propyl-N-p-toluenesulfonyl]aminobenzoate 

Downstream Products

• 165310-94-1 5-ethoxy-carbonylmethylidene-7-chloro-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine 
• 331947-66-1 (+)-Tolvaptan 
• 331947-44-5 (-)-Tolvaptan 
• 1296212-17-3 N-(4-(7-chloro-5-hydroxy-2,3,4-trihydro-5-deutero-1H-benzo[b]azepine-1-carbonyl)-3-methylphenyl)-2-methylbenzamide 
• 150683-30-0 tolvaptan 

Relevant articles and documents

Efficient and promising asymmetric preparation of enantiopure tolvaptan via transfer hydrogenation with robust catalysts

Enantiopure tolvaptan, the first and only oral vasopressin antagonist for hyponatremia has been prepared by using an asymmetric transfer hydrogenation as a key step with HCOOH-Et3N or HCOONa-H2O as the hydrogen donor in open air. Good chemical yields with up to 99% enantioselectivity were obtained with a 1000:1 of S/C in an HCOONa-H2O system. The air and water stable catalysts provide a very promising prospect for industrial application.

INTERMEDIATES AND METHODS FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES

The present invention relates to new intermediates for the synthesis of tolvaptan and its derivatives, as well as a method for its preparation involving said intermediates.

Novel benzoazepine compound, composition and applications of novel benzoazepine compound and composition

The invention relates to a novel benzoazepine compound, which comprises a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition containing the compound and the pharmaceutically acceptable salt thereof. The pres

Method for preparing high-purity tolvaptan intermediate

The invention provides a method for preparing a high-purity tolvaptan intermediate, and concretely provides a method for purifying a tolvaptan intermediate N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepine-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide (formula II). A crude product containing the compound of formula II is recrystallized by an organic solvent composed of ester, haloalkaneand ether to preferably obtain the compound of formula II, having a purity of above 99.00%.